Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Evidence available on the effectiveness and costs of biological therapies for the initial treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a population-based cohort investigation for assessing overall survival and costs associated with their use in a real-worl...

Full description

Bibliographic Details
Main Authors: Matteo Franchi, Donatella Garau, Ursula Kirchmayer, Mirko Di Martino, Marilena Romero, Ilenia De Carlo, Salvatore Scondotto, Giovanni Corrao
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
colorectal cancer
target therapy
effectiveness
cost-effectiveness
survival
long-term outcomes
Online Access:https://www.mdpi.com/2072-6694/12/4/839

Internet

https://www.mdpi.com/2072-6694/12/4/839

Similar Items